Industry Research Reports

Home > Reports > Medical Care > Global Rheumatoid Arthritis (RA) Drugs Market Research Report 2026

Global Rheumatoid Arthritis (RA) Drugs Market Research Report 2026

Industry: Medical Care

Published Date: 2026-04-27

Pages: 118 Pages

Report ld: 6651792

Request Sample

Pre-Order Enquiry

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

Description
Table of Contents
Table of Figures
Related Reports
PDF Download

The global Rheumatoid Arthritis (RA) Drugs market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.

Rheumatoid arthritis (RA) is an inflammatory disease that progresses over time affecting the joints. The symptoms aggravate over time, which is why medication for RA becomes essential to stop the inflammation. There is no permanent cure for rheumatoid arthritis, though increasing research activities regarding the same indicate that remission of symptoms is achieved when treatment begins in the initial stages with strong medications known as disease-modifying antirheumatic drugs (DMARDs).

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report delivers a comprehensive overview of the global Rheumatoid Arthritis (RA) Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Rheumatoid Arthritis (RA) Drugs. The Rheumatoid Arthritis (RA) Drugs market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Rheumatoid Arthritis (RA) Drugs market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Rheumatoid Arthritis (RA) Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

By Company

AbbVie
Roche
Merck
HEYL Chemisch-pharmazeutische Fabrik
Johnson & Johnson
Amgen, Inc.
Pfizer
Bristol-Myers Squibb
UCB
GSK
Sanofi
Abbott Laboratories
Teva Pharmaceutical

Consumption by Region

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
Latin America
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA

Segment by Type

NSAIDs
Analgesic Drugs
Corticosteroids
DMARDs
Biological Therapies
JAK-inhibitors

Segment by Application

Hospitals
Clinics
Others

biaoTi Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.

Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.

Chapter 3: Provides a detailed view of the competitive landscape for Rheumatoid Arthritis (RA) Drugs companies, covering revenue share, development plans, and mergers and acquisitions.

Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.

Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.

Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.

Chapter 12: Key findings and conclusions of the report.

biaoTi Why This Report?

Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:

Market entry risks/opportunities by region

We identify regional market threats and growth prospects to guide your overseas layout.

Product mix optimization based on local practices

We adjust product portfolios in line with local consumption habits.

Competitor tactics in fragmented vs. consolidated markets

We unpack rivals’ operation strategies for scattered and highly concentrated industries.

Full Research Coverage

We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.

19 Years Industry Expertise

We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.

24/7 Fast Report Delivery

Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.

Localized Strategic Analysis

We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.

Market entry risks/opportunities by region

All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.

Market entry risks/opportunities by region

We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.

Table of Contents

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Rheumatoid Arthritis (RA) Drugs Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 NSAIDs

1.2.3 Analgesic Drugs

1.2.4 Corticosteroids

1.2.5 DMARDs

1.2.6 Biological Therapies

1.2.7 JAK-inhibitors

1.3 Market by Application

1.3.1 Global Rheumatoid Arthritis (RA) Drugs Market Growth by Application: 2021 vs 2025 vs 2032

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Rheumatoid Arthritis (RA) Drugs Market Perspective (2021–2032)

2.2 Global Rheumatoid Arthritis (RA) Drugs Growth Trends by Region

2.2.1 Global Rheumatoid Arthritis (RA) Drugs Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Rheumatoid Arthritis (RA) Drugs Historic Market Size by Region (2021–2026)

2.2.3 Rheumatoid Arthritis (RA) Drugs Forecasted Market Size by Region (2027–2032)

2.3 Rheumatoid Arthritis (RA) Drugs Market Dynamics

2.3.1 Rheumatoid Arthritis (RA) Drugs Industry Trends

2.3.2 Rheumatoid Arthritis (RA) Drugs Market Drivers

2.3.3 Rheumatoid Arthritis (RA) Drugs Market Challenges

2.3.4 Rheumatoid Arthritis (RA) Drugs Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Rheumatoid Arthritis (RA) Drugs Players by Revenue

3.1.1 Global Top Rheumatoid Arthritis (RA) Drugs Players by Revenue (2021–2026)

3.1.2 Global Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Players (2021–2026)

3.2 Global Top Rheumatoid Arthritis (RA) Drugs Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Rheumatoid Arthritis (RA) Drugs Revenue

3.4 Global Rheumatoid Arthritis (RA) Drugs Market Concentration Ratio

3.4.1 Global Rheumatoid Arthritis (RA) Drugs Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Rheumatoid Arthritis (RA) Drugs Revenue in 2025

3.5 Global Key Players of Rheumatoid Arthritis (RA) Drugs Head Offices and Areas Served

3.6 Global Key Players of Rheumatoid Arthritis (RA) Drugs, Products and Applications

3.7 Global Key Players of Rheumatoid Arthritis (RA) Drugs, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Rheumatoid Arthritis (RA) Drugs Breakdown Data by Type

4.1 Global Rheumatoid Arthritis (RA) Drugs Historic Market Size by Type (2021–2026)

4.2 Global Rheumatoid Arthritis (RA) Drugs Forecasted Market Size by Type (2027–2032)

5 Rheumatoid Arthritis (RA) Drugs Breakdown Data by Application

5.1 Global Rheumatoid Arthritis (RA) Drugs Historic Market Size by Application (2021–2026)

5.2 Global Rheumatoid Arthritis (RA) Drugs Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Rheumatoid Arthritis (RA) Drugs Market Size (2021–2032)

6.2 North America Rheumatoid Arthritis (RA) Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Rheumatoid Arthritis (RA) Drugs Market Size by Country (2021–2026)

6.4 North America Rheumatoid Arthritis (RA) Drugs Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Rheumatoid Arthritis (RA) Drugs Market Size (2021–2032)

7.2 Europe Rheumatoid Arthritis (RA) Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Rheumatoid Arthritis (RA) Drugs Market Size by Country (2021–2026)

7.4 Europe Rheumatoid Arthritis (RA) Drugs Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Rheumatoid Arthritis (RA) Drugs Market Size (2021–2032)

8.2 Asia-Pacific Rheumatoid Arthritis (RA) Drugs Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Rheumatoid Arthritis (RA) Drugs Market Size by Region (2021–2026)

8.4 Asia-Pacific Rheumatoid Arthritis (RA) Drugs Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Rheumatoid Arthritis (RA) Drugs Market Size (2021–2032)

9.2 Latin America Rheumatoid Arthritis (RA) Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Rheumatoid Arthritis (RA) Drugs Market Size by Country (2021–2026)

9.4 Latin America Rheumatoid Arthritis (RA) Drugs Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Rheumatoid Arthritis (RA) Drugs Market Size (2021–2032)

10.2 Middle East & Africa Rheumatoid Arthritis (RA) Drugs Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Rheumatoid Arthritis (RA) Drugs Market Size by Country (2021–2026)

10.4 Middle East & Africa Rheumatoid Arthritis (RA) Drugs Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 AbbVie

11.1.1 AbbVie Company Details

11.1.2 AbbVie Business Overview

11.1.3 AbbVie Rheumatoid Arthritis (RA) Drugs Introduction

11.1.4 AbbVie Revenue in Rheumatoid Arthritis (RA) Drugs Business (2021–2026)

11.1.5 AbbVie Recent Development

11.2 Roche

11.2.1 Roche Company Details

11.2.2 Roche Business Overview

11.2.3 Roche Rheumatoid Arthritis (RA) Drugs Introduction

11.2.4 Roche Revenue in Rheumatoid Arthritis (RA) Drugs Business (2021–2026)

11.2.5 Roche Recent Development

11.3 Merck

11.3.1 Merck Company Details

11.3.2 Merck Business Overview

11.3.3 Merck Rheumatoid Arthritis (RA) Drugs Introduction

11.3.4 Merck Revenue in Rheumatoid Arthritis (RA) Drugs Business (2021–2026)

11.3.5 Merck Recent Development

11.4 HEYL Chemisch-pharmazeutische Fabrik

11.4.1 HEYL Chemisch-pharmazeutische Fabrik Company Details

11.4.2 HEYL Chemisch-pharmazeutische Fabrik Business Overview

11.4.3 HEYL Chemisch-pharmazeutische Fabrik Rheumatoid Arthritis (RA) Drugs Introduction

11.4.4 HEYL Chemisch-pharmazeutische Fabrik Revenue in Rheumatoid Arthritis (RA) Drugs Business (2021–2026)

11.4.5 HEYL Chemisch-pharmazeutische Fabrik Recent Development

11.5 Johnson & Johnson

11.5.1 Johnson & Johnson Company Details

11.5.2 Johnson & Johnson Business Overview

11.5.3 Johnson & Johnson Rheumatoid Arthritis (RA) Drugs Introduction

11.5.4 Johnson & Johnson Revenue in Rheumatoid Arthritis (RA) Drugs Business (2021–2026)

11.5.5 Johnson & Johnson Recent Development

11.6 Amgen, Inc.

11.6.1 Amgen, Inc. Company Details

11.6.2 Amgen, Inc. Business Overview

11.6.3 Amgen, Inc. Rheumatoid Arthritis (RA) Drugs Introduction

11.6.4 Amgen, Inc. Revenue in Rheumatoid Arthritis (RA) Drugs Business (2021–2026)

11.6.5 Amgen, Inc. Recent Development

11.7 Pfizer

11.7.1 Pfizer Company Details

11.7.2 Pfizer Business Overview

11.7.3 Pfizer Rheumatoid Arthritis (RA) Drugs Introduction

11.7.4 Pfizer Revenue in Rheumatoid Arthritis (RA) Drugs Business (2021–2026)

11.7.5 Pfizer Recent Development

11.8 Bristol-Myers Squibb

11.8.1 Bristol-Myers Squibb Company Details

11.8.2 Bristol-Myers Squibb Business Overview

11.8.3 Bristol-Myers Squibb Rheumatoid Arthritis (RA) Drugs Introduction

11.8.4 Bristol-Myers Squibb Revenue in Rheumatoid Arthritis (RA) Drugs Business (2021–2026)

11.8.5 Bristol-Myers Squibb Recent Development

11.9 UCB

11.9.1 UCB Company Details

11.9.2 UCB Business Overview

11.9.3 UCB Rheumatoid Arthritis (RA) Drugs Introduction

11.9.4 UCB Revenue in Rheumatoid Arthritis (RA) Drugs Business (2021–2026)

11.9.5 UCB Recent Development

11.10 GSK

11.10.1 GSK Company Details

11.10.2 GSK Business Overview

11.10.3 GSK Rheumatoid Arthritis (RA) Drugs Introduction

11.10.4 GSK Revenue in Rheumatoid Arthritis (RA) Drugs Business (2021–2026)

11.10.5 GSK Recent Development

11.11 Sanofi

11.11.1 Sanofi Company Details

11.11.2 Sanofi Business Overview

11.11.3 Sanofi Rheumatoid Arthritis (RA) Drugs Introduction

11.11.4 Sanofi Revenue in Rheumatoid Arthritis (RA) Drugs Business (2021–2026)

11.11.5 Sanofi Recent Development

11.12 Abbott Laboratories

11.12.1 Abbott Laboratories Company Details

11.12.2 Abbott Laboratories Business Overview

11.12.3 Abbott Laboratories Rheumatoid Arthritis (RA) Drugs Introduction

11.12.4 Abbott Laboratories Revenue in Rheumatoid Arthritis (RA) Drugs Business (2021–2026)

11.12.5 Abbott Laboratories Recent Development

11.13 Teva Pharmaceutical

11.13.1 Teva Pharmaceutical Company Details

11.13.2 Teva Pharmaceutical Business Overview

11.13.3 Teva Pharmaceutical Rheumatoid Arthritis (RA) Drugs Introduction

11.13.4 Teva Pharmaceutical Revenue in Rheumatoid Arthritis (RA) Drugs Business (2021–2026)

11.13.5 Teva Pharmaceutical Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

Table of Figures

List of Tables

Table 1. Global Rheumatoid Arthritis (RA) Drugs Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of NSAIDs

Table 3. Key Players of Analgesic Drugs

Table 4. Key Players of Corticosteroids

Table 5. Key Players of DMARDs

Table 6. Key Players of Biological Therapies

Table 7. Key Players of JAK-inhibitors

Table 8. Global Rheumatoid Arthritis (RA) Drugs Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 9. Global Rheumatoid Arthritis (RA) Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 10. Global Rheumatoid Arthritis (RA) Drugs Market Size by Region (US$ Million), 2021–2026

Table 11. Global Rheumatoid Arthritis (RA) Drugs Market Share by Region (2021–2026)

Table 12. Global Rheumatoid Arthritis (RA) Drugs Forecasted Market Size by Region (US$ Million), 2027–2032

Table 13. Global Rheumatoid Arthritis (RA) Drugs Market Share by Region (2027–2032)

Table 14. Rheumatoid Arthritis (RA) Drugs Market Trends

Table 15. Rheumatoid Arthritis (RA) Drugs Market Drivers

Table 16. Rheumatoid Arthritis (RA) Drugs Market Challenges

Table 17. Rheumatoid Arthritis (RA) Drugs Market Restraints

Table 18. Global Rheumatoid Arthritis (RA) Drugs Revenue by Players (US$ Million), 2021–2026

Table 19. Global Rheumatoid Arthritis (RA) Drugs Market Share by Players (2021–2026)

Table 20. Global Top Rheumatoid Arthritis (RA) Drugs Players by Tier (Tier 1, Tier 2, and Tier 3), based on Rheumatoid Arthritis (RA) Drugs Revenue, 2025

Table 21. Ranking of Global Top Rheumatoid Arthritis (RA) Drugs Companies by Revenue (US$ Million) in 2025

Table 22. Global 5 Largest Players Market Share by Rheumatoid Arthritis (RA) Drugs Revenue (CR5 and HHI), 2021–2026

Table 23. Global Key Players of Rheumatoid Arthritis (RA) Drugs, Headquarters and Area Served

Table 24. Global Key Players of Rheumatoid Arthritis (RA) Drugs, Products and Applications

Table 25. Global Key Players of Rheumatoid Arthritis (RA) Drugs, Date of General Availability (GA)

Table 26. Mergers and Acquisitions, Expansion Plans

Table 27. Global Rheumatoid Arthritis (RA) Drugs Market Size by Type (US$ Million), 2021–2026

Table 28. Global Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Type (2021–2026)

Table 29. Global Rheumatoid Arthritis (RA) Drugs Forecasted Market Size by Type (US$ Million), 2027–2032

Table 30. Global Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Type (2027–2032)

Table 31. Global Rheumatoid Arthritis (RA) Drugs Market Size by Application (US$ Million), 2021–2026

Table 32. Global Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Application (2021–2026)

Table 33. Global Rheumatoid Arthritis (RA) Drugs Forecasted Market Size by Application (US$ Million), 2027–2032

Table 34. Global Rheumatoid Arthritis (RA) Drugs Revenue Market Share by Application (2027–2032)

Table 35. North America Rheumatoid Arthritis (RA) Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 36. North America Rheumatoid Arthritis (RA) Drugs Market Size by Country (US$ Million), 2021–2026

Table 37. North America Rheumatoid Arthritis (RA) Drugs Market Size by Country (US$ Million), 2027–2032

Table 38. Europe Rheumatoid Arthritis (RA) Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 39. Europe Rheumatoid Arthritis (RA) Drugs Market Size by Country (US$ Million), 2021–2026

Table 40. Europe Rheumatoid Arthritis (RA) Drugs Market Size by Country (US$ Million), 2027–2032

Table 41. Asia-Pacific Rheumatoid Arthritis (RA) Drugs Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 42. Asia-Pacific Rheumatoid Arthritis (RA) Drugs Market Size by Region (US$ Million), 2021–2026

Table 43. Asia-Pacific Rheumatoid Arthritis (RA) Drugs Market Size by Region (US$ Million), 2027–2032

Table 44. Latin America Rheumatoid Arthritis (RA) Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 45. Latin America Rheumatoid Arthritis (RA) Drugs Market Size by Country (US$ Million), 2021–2026

Table 46. Latin America Rheumatoid Arthritis (RA) Drugs Market Size by Country (US$ Million), 2027–2032

Table 47. Middle East & Africa Rheumatoid Arthritis (RA) Drugs Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 48. Middle East & Africa Rheumatoid Arthritis (RA) Drugs Market Size by Country (US$ Million), 2021–2026

Table 49. Middle East & Africa Rheumatoid Arthritis (RA) Drugs Market Size by Country (US$ Million), 2027–2032

Table 50. AbbVie Company Details

Table 51. AbbVie Business Overview

Table 52. AbbVie Rheumatoid Arthritis (RA) Drugs Product

Table 53. AbbVie Revenue in Rheumatoid Arthritis (RA) Drugs Business (US$ Million), 2021–2026

Table 54. AbbVie Recent Development

Table 55. Roche Company Details

Table 56. Roche Business Overview

Table 57. Roche Rheumatoid Arthritis (RA) Drugs Product

Table 58. Roche Revenue in Rheumatoid Arthritis (RA) Drugs Business (US$ Million), 2021–2026

Table 59. Roche Recent Development

Table 60. Merck Company Details

Table 61. Merck Business Overview

Table 62. Merck Rheumatoid Arthritis (RA) Drugs Product

Table 63. Merck Revenue in Rheumatoid Arthritis (RA) Drugs Business (US$ Million), 2021–2026

Table 64. Merck Recent Development

Table 65. HEYL Chemisch-pharmazeutische Fabrik Company Details

Table 66. HEYL Chemisch-pharmazeutische Fabrik Business Overview

Table 67. HEYL Chemisch-pharmazeutische Fabrik Rheumatoid Arthritis (RA) Drugs Product

Table 68. HEYL Chemisch-pharmazeutische Fabrik Revenue in Rheumatoid Arthritis (RA) Drugs Business (US$ Million), 2021–2026

Table 69. HEYL Chemisch-pharmazeutische Fabrik Recent Development

Table 70. Johnson & Johnson Company Details

Table 71. Johnson & Johnson Business Overview

Table 72. Johnson & Johnson Rheumatoid Arthritis (RA) Drugs Product

Table 73. Johnson & Johnson Revenue in Rheumatoid Arthritis (RA) Drugs Business (US$ Million), 2021–2026

Table 74. Johnson & Johnson Recent Development

Table 75. Amgen, Inc. Company Details

Table 76. Amgen, Inc. Business Overview

Table 77. Amgen, Inc. Rheumatoid Arthritis (RA) Drugs Product

Table 78. Amgen, Inc. Revenue in Rheumatoid Arthritis (RA) Drugs Business (US$ Million), 2021–2026

Table 79. Amgen, Inc. Recent Development

Table 80. Pfizer Company Details

Table 81. Pfizer Business Overview

Table 82. Pfizer Rheumatoid Arthritis (RA) Drugs Product

Table 83. Pfizer Revenue in Rheumatoid Arthritis (RA) Drugs Business (US$ Million), 2021–2026

Table 84. Pfizer Recent Development

Table 85. Bristol-Myers Squibb Company Details

Table 86. Bristol-Myers Squibb Business Overview

Table 87. Bristol-Myers Squibb Rheumatoid Arthritis (RA) Drugs Product

Table 88. Bristol-Myers Squibb Revenue in Rheumatoid Arthritis (RA) Drugs Business (US$ Million), 2021–2026

Table 89. Bristol-Myers Squibb Recent Development

Table 90. UCB Company Details

Table 91. UCB Business Overview

Table 92. UCB Rheumatoid Arthritis (RA) Drugs Product

Table 93. UCB Revenue in Rheumatoid Arthritis (RA) Drugs Business (US$ Million), 2021–2026

Table 94. UCB Recent Development

Table 95. GSK Company Details

Table 96. GSK Business Overview

Table 97. GSK Rheumatoid Arthritis (RA) Drugs Product

Table 98. GSK Revenue in Rheumatoid Arthritis (RA) Drugs Business (US$ Million), 2021–2026

Table 99. GSK Recent Development

Table 100. Sanofi Company Details

Table 101. Sanofi Business Overview

Table 102. Sanofi Rheumatoid Arthritis (RA) Drugs Product

Table 103. Sanofi Revenue in Rheumatoid Arthritis (RA) Drugs Business (US$ Million), 2021–2026

Table 104. Sanofi Recent Development

Table 105. Abbott Laboratories Company Details

Table 106. Abbott Laboratories Business Overview

Table 107. Abbott Laboratories Rheumatoid Arthritis (RA) Drugs Product

Table 108. Abbott Laboratories Revenue in Rheumatoid Arthritis (RA) Drugs Business (US$ Million), 2021–2026

Table 109. Abbott Laboratories Recent Development

Table 110. Teva Pharmaceutical Company Details

Table 111. Teva Pharmaceutical Business Overview

Table 112. Teva Pharmaceutical Rheumatoid Arthritis (RA) Drugs Product

Table 113. Teva Pharmaceutical Revenue in Rheumatoid Arthritis (RA) Drugs Business (US$ Million), 2021–2026

Table 114. Teva Pharmaceutical Recent Development

Table 115. Research Programs/Design for This Report

Table 116. Key Data Information from Secondary Sources

Table 117. Key Data Information from Primary Sources

Table 118. Authors List of This Report

List of Figures

Figure 1. Rheumatoid Arthritis (RA) Drugs Picture

Figure 2. Global Rheumatoid Arthritis (RA) Drugs Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global Rheumatoid Arthritis (RA) Drugs Market Share by Type: 2025 vs 2032

Figure 4. NSAIDs Features

Figure 5. Analgesic Drugs Features

Figure 6. Corticosteroids Features

Figure 7. DMARDs Features

Figure 8. Biological Therapies Features

Figure 9. JAK-inhibitors Features

Figure 10. Global Rheumatoid Arthritis (RA) Drugs Market Size by Application (US$ Million), 2021–2032

Figure 11. Global Rheumatoid Arthritis (RA) Drugs Market Share by Application: 2025 vs 2032

Figure 12. Hospitals Case Studies

Figure 13. Clinics Case Studies

Figure 14. Others Case Studies

Figure 15. Rheumatoid Arthritis (RA) Drugs Report Years Considered

Figure 16. Global Rheumatoid Arthritis (RA) Drugs Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 17. Global Rheumatoid Arthritis (RA) Drugs Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 18. Global Rheumatoid Arthritis (RA) Drugs Market Share by Region: 2025 vs 2032

Figure 19. Global Rheumatoid Arthritis (RA) Drugs Market Share by Players in 2025

Figure 20. Global Rheumatoid Arthritis (RA) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 21. The Top 10 and 5 Players Market Share by Rheumatoid Arthritis (RA) Drugs Revenue in 2025

Figure 22. North America Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 23. North America Rheumatoid Arthritis (RA) Drugs Market Share by Country (2021–2032)

Figure 24. United States Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 25. Canada Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 26. Europe Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 27. Europe Rheumatoid Arthritis (RA) Drugs Market Share by Country (2021–2032)

Figure 28. Germany Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 29. France Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 30. U.K. Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. Italy Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 32. Russia Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 33. Ireland Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. Asia-Pacific Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. Asia-Pacific Rheumatoid Arthritis (RA) Drugs Market Share by Region (2021–2032)

Figure 36. China Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. Japan Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. South Korea Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Southeast Asia Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. India Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 41. Australia & New Zealand Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. Latin America Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Latin America Rheumatoid Arthritis (RA) Drugs Market Share by Country (2021–2032)

Figure 44. Mexico Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 45. Brazil Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. Middle East & Africa Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. Middle East & Africa Rheumatoid Arthritis (RA) Drugs Market Share by Country (2021–2032)

Figure 48. Israel Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 49. Saudi Arabia Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 50. UAE Rheumatoid Arthritis (RA) Drugs Market Size YoY Growth (US$ Million), 2021–2032

Figure 51. AbbVie Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2021–2026)

Figure 52. Roche Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2021–2026)

Figure 53. Merck Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2021–2026)

Figure 54. HEYL Chemisch-pharmazeutische Fabrik Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2021–2026)

Figure 55. Johnson & Johnson Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2021–2026)

Figure 56. Amgen, Inc. Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2021–2026)

Figure 57. Pfizer Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2021–2026)

Figure 58. Bristol-Myers Squibb Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2021–2026)

Figure 59. UCB Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2021–2026)

Figure 60. GSK Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2021–2026)

Figure 61. Sanofi Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2021–2026)

Figure 62. Abbott Laboratories Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2021–2026)

Figure 63. Teva Pharmaceutical Revenue Growth Rate in Rheumatoid Arthritis (RA) Drugs Business (2021–2026)

Figure 64. Bottom-up and Top-down Approaches for This Report

Figure 65. Data Triangulation

Figure 66. Key Executives Interviewed

Related Reports

Rheumatoid Arthritis (RA) Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Rheumatoid arthritis (RA) is an inflammatory disease that progresses over time affecting the joints. The symptoms aggravate over time, which is why medication for RA becomes essential to stop the inflammation. There is no permanent cure for rheumatoid arthritis, though increasing research activities regarding the same indicate that remission of symptoms is achieved when treatment begins in the initial stages with strong medications known as disease-modifying antirheumatic drugs (DMARDs).
Published Date: 2024-01-24
Pages: 101
USD 3950.00
(Single User License)
Global Rheumatoid Arthritis (RA) Drugs Market Research Report 2024
Rheumatoid arthritis (RA) is an inflammatory disease that progresses over time affecting the joints. The symptoms aggravate over time, which is why medication for RA becomes essential to stop the inflammation. There is no permanent cure for rheumatoid arthritis, though increasing research activities regarding the same indicate that remission of symptoms is achieved when treatment begins in the initial stages with strong medications known as disease-modifying antirheumatic drugs (DMARDs).
Published Date: 2024-01-31
Pages: 87
USD 2900.00
(Single User License)
Global Rheumatoid Arthritis (RA) Drugs Market Insights, Forecast to 2030
Rheumatoid arthritis (RA) is an inflammatory disease that progresses over time affecting the joints. The symptoms aggravate over time, which is why medication for RA becomes essential to stop the inflammation. There is no permanent cure for rheumatoid arthritis, though increasing research activities regarding the same indicate that remission of symptoms is achieved when treatment begins in the initial stages with strong medications known as disease-modifying antirheumatic drugs (DMARDs).
Published Date: 2024-04-26
Pages: 107
USD 4900.00
(Single User License)
Global Rheumatoid Arthritis (RA) Drugs Market Research Report 2025
The global market for Rheumatoid Arthritis (RA) Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-02-27
Pages: 85
USD 2900.00
(Single User License)
Rheumatoid Arthritis (RA) Drugs- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Rheumatoid Arthritis (RA) Drugs was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-02-27
Pages: 120
USD 3950.00
(Single User License)
Global Rheumatoid Arthritis (RA) Drugs Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Rheumatoid Arthritis (RA) Drugs market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-09-06
Pages: 92
USD 4250.00
(Single User License)
Rheumatoid Arthritis (RA) Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Rheumatoid Arthritis (RA) Drugs was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published Date: 2026-07-14
Pages: 111
USD 3950.00
(Single User License)

Rheumatoid Arthritis (RA) Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Rheumatoid arthritis (RA) is an inflammatory disease that progresses over time affecting the joints. The symptoms aggravate over time, which is why medication for RA becomes essential to stop the inflammation. There is no permanent cure for rheumatoid arthritis, though increasing research activities regarding the same indicate that remission of symptoms is achieved when treatment begins in the initial stages with strong medications known as disease-modifying antirheumatic drugs (DMARDs).
Published: 2024-01-24
Pages: 101
USD 3950.00 (Single User License)
Global Rheumatoid Arthritis (RA) Drugs Market Research Report 2024
Rheumatoid arthritis (RA) is an inflammatory disease that progresses over time affecting the joints. The symptoms aggravate over time, which is why medication for RA becomes essential to stop the inflammation. There is no permanent cure for rheumatoid arthritis, though increasing research activities regarding the same indicate that remission of symptoms is achieved when treatment begins in the initial stages with strong medications known as disease-modifying antirheumatic drugs (DMARDs).
Published: 2024-01-31
Pages: 87
USD 2900.00 (Single User License)
Global Rheumatoid Arthritis (RA) Drugs Market Insights, Forecast to 2030
Rheumatoid arthritis (RA) is an inflammatory disease that progresses over time affecting the joints. The symptoms aggravate over time, which is why medication for RA becomes essential to stop the inflammation. There is no permanent cure for rheumatoid arthritis, though increasing research activities regarding the same indicate that remission of symptoms is achieved when treatment begins in the initial stages with strong medications known as disease-modifying antirheumatic drugs (DMARDs).
Published: 2024-04-26
Pages: 107
USD 4900.00 (Single User License)
Global Rheumatoid Arthritis (RA) Drugs Market Research Report 2025
The global market for Rheumatoid Arthritis (RA) Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-02-27
Pages: 85
USD 2900.00 (Single User License)
Rheumatoid Arthritis (RA) Drugs- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Rheumatoid Arthritis (RA) Drugs was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-02-27
Pages: 120
USD 3950.00 (Single User License)
Global Rheumatoid Arthritis (RA) Drugs Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Rheumatoid Arthritis (RA) Drugs market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-09-06
Pages: 92
USD 4250.00 (Single User License)
Rheumatoid Arthritis (RA) Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Rheumatoid Arthritis (RA) Drugs was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published: 2026-07-14
Pages: 111
USD 3950.00 (Single User License)